Developmentally regulated GTP binding protein 2 (DRG2) and Nup107 are associated with epigenetic regulation via H2A.Z on promoter regions of specific genes in MCF7 breast cancer cells

Abstract

Background: Epigenetic changes are critical events in breast cancer development. The regulation of epigenetic marks is orchestrated by DNA methylation, modifications of canonical histones, and incorporation of histone variants. A histone variant of H2A.Z was recently reported to be associated with breast cancer progression. However, the physiological function of H2A.Z in breast cancer has yet to be revealed. We previously identified genetic interactions between H2AvD (Drosophila H2A.Z) and DRG2 by means of Drosophila screening.

Results: We herein focused on identifying new factors associated with DRG2 in order to reveal the epigenetic impact of H2A.Z on breast cancer. Initially, in a series of protein purification assays with a Drosophila cell line, we identified Nup107, a nuclear pore complex protein, as one of the factors interacting with DRG2. In addition, RWD domain containing 1 (RWDD1), GCN1 like protein 1 (GCN1L1), eukaryotic translation initiation factor 4B (eIF4B), and argininosuccinate lyase (ASL) were co-purified. Next, employing chromatin immunoprecipitation-microarray analysis on the human breast cancer cell line MCF7, we revealed that H2A.Z, DRG2, and Nup107 co-occupy the promoter regions of 1,947 genes. In the common genes showing co-occupation with these three factors, the largest category, which included 871 genes, was found to consist of ‘alternative splicing variants’. This result and the factors co-purified suggest that H2A.Z, DRG2, and Nup107 co-regulate mRNA splicing as well as nuclear export and translation.

Conclusions: Further analysis focusing on the biological functions of DRG2 and Nup107 would facilitate elucidating the epigenetic impact of H2A.Z on breast cancer development.

Keywords: Breast cancer; H2A.Z; Estrogen; Estrogen receptor; DRG2; Nup107; Epigenetics

Abbreviations: ASL: Argininosuccinate Lyase; ChIP: Chromatin Immunoprecipitation; ChIP-chip: ChIP-Microarray Analysis; DRG2: Developmentally Regulated GTP Binding Protein 2; eIF4B: Eukaryotic Translation Initiation Factor 4B; E2: Estrogen; ER: Estrogen receptor; GCN1L1: GCN1 like protein 1; RWDD1: RWD Domain containing 1; S2 cells: Drosophila Schneider cells

Citation: Tanabe M, Fujiyama S, Horimoto Y. Developmentally regulated GTP binding protein 2 (DRG2) and Nup107 are associated with epigenetic regulation via H2A.Z on promoter regions of specific genes in MCF7 breast cancer cells. J Clin Epigenet. 2016, 2:4.
**Background**

Breast cancer is caused by the accumulation of somatic mutations, but factors that directly regulate disease progression are as yet poorly understood [1]. It is well known that approximately 90% of breast cancers are sporadic. Therefore, it is speculated that epigenetic changes without sequential mutation of DNA, along with somatic mutations, are themselves significant. Epidemiological studies have demonstrated that environmental, dietary, and lifestyle factors impact the occurrence of breast cancer, and it is well known that high lifetime exposure to estrogen (E2) increases the risk of breast cancer [2]. E2 plays critical roles in the initiation and development of breast cancer [3,4]. Biological functions of E2 are mediated through estrogen receptor (ER) α/β. ERs are ligand-dependent transcriptional factors essential for the expressions of ER-target genes. Epigenetic changes of ERα-target genes are critical for the development and progression of breast cancer [3]. However, the mechanism by which a single epidemiologic factor, such as E2 stimulation, can alter epigenetic marks on ER target genes has not been elucidated. We are interested in alterations of epigenetic marks, in response to lifetime E2 exposure, which may potentiate breast cancer initiation and development.

In addition to DNA methylation and modifications of canonical histones, several histone variants function as epigenetic marks in gene expression [5-9], meaning that regulation of gene expressions includes the replacement of canonical histones with histone variants as well as post-translational modifications of the tails of both the canonical histones and their variants [5]. H2A.Z, one such histone H2A variant, was reported to be essential for transcriptional activation of ERα-target genes [10]. Recently, the clinical impacts of H2A.Z on breast cancer development have attracted attention [1,5,11]. High expression of H2A.Z was shown to be significantly associated with breast cancer proliferation, development [11], progression and lymph node metastasis [12]. However, the molecular mechanism by which H2A.Z regulates the proliferation and progression of breast cancer has yet to be revealed.

H2A.Z, which is highly conserved from yeast to humans, was experimentally confirmed to be essential for survival in *Drosophila* and mice [13, 14], suggesting that H2A.Z has important functions that cannot be carried out by canonical histones [5]. H2A.Z is mainly localized in active gene promoters and regulates gene expressions [6-9]. While the *Drosophila* H2A.Z homologue of H2AvD has been well studied in terms of its function and interactions with other factors, by both genetic and biochemical approaches, there has been little investigation of the biological functions of human H2A.Z. Thus, we employed several *Drosophila* screening systems and protein purification methods, as previously described [15-20], in efforts to identify novel factors associated with epigenetic regulation that is dependent on H2AvD. Employing these experimental approaches, we previously identified developmentally regulated GTP binding protein 2 (DRG2) as a novel factor genetically associated with H2AvD. The DRG2 gene encodes a 364 amino acid protein involved in cell proliferation and differentiation [21-24]. However, to our knowledge, there have been no studies demonstrating DRG2 to function in the nucleus. Therefore, whether DRG2 associates with H2A.Z/H2AvD on chromatin remains unknown. Herein, we investigated the molecular function of DRG2 in the nucleus, and revealed the mechanism by which DRG2 associates with H2A.Z by applying protein complex purification and chromatin immunoprecipitation-microarray analysis.

**Materials and Methods**

**Purification of protein complex**: Biochemical protein complex purification was performed as described in previous reports [15-18]. *Drosophila* Schneider (S2) cells were cultured in Schneider’s *Drosophila* Medium (Gibco BRL, Grand Island, NY) supplemented with 10 % fetal bovine serum at 25 °C. For purification of the *Drosophila* DRG2 (dDRG2)-associated complex, S2 cells stably expressing FLAG-His-dDRG2 were established by co-transfection of FLAG-His-tagged-dDRG2 expression plasmid cloned into the pAct vector (Promega, Madison, WI; GenBank accession no. AF264723) and pCoBlast vector (Invitrogen), and were selected by adding 25 mg/mL Blasticidin. Nuclear extracts of S2 cells (Mock) and FLAG-His-dDRG2 expressing S2 cells, which had been prepared as described previously [15-18], were incubated at 4°C with 40 μL of anti-FLAG M2 agarose (Sigma) for 6 h. After being washed five times with buffer D (20 mM HEPES-KOH, 0.2 mM EDTA, 5 mM MgCl2, 150 mM KCl, 0.05% [v/v] NP-40, 10% [v/v] glycerol, 0.5 mM DTT, 0.2 mM PMSF, protease inhibitor cocktail [Roche] at pH 7.9), the protein complex was eluted with 20 μL/ml FLAG peptide (Sigma) in buffer D. Ni-NTA Agarose (QIAGEN) was used for further His-tag affinity purification. The samples obtained were analyzed by SDS-PAGE followed by silver staining.

**Glyceral density gradient centrifugation**: In order to fractionate protein complexes according to their molecular weights, glycerol density gradient centrifugation was performed as previously described [15]. The eluted complex was fractionated by 10–50% glycerol density gradient centrifugation at 4°C, 182,000 g using a SW-40 rotor (Beckman Coulter) for 16 h. Gradients were fractionated into 1 mL each and the obtained fractions were analyzed by Western blotting with the antibody against DRG2 (AF264723) and pCoBlast vector (Invitrogen), and were selected.

**Chromatin immunoprecipitation (ChIP)**: Chromatin immunoprecipitation (ChIP) and ChIP-microarray analysis (ChIP-chip): ChIP analysis using a breast cancer cell line of MCF7 was performed according to the protocol previously reported by ACTGen (Nagano, Japan) [25]. Antibodies of DRG2 were detected in the ChIP experiments.
(sc164233, Santa Cruz biotechnology), Nup107 (ab85916, Abcam), and H2A.Z (ab4174, Abcam) were used for ChIP analysis. ChIP-chip service and analysis were performed at MBL (Nagoya, Japan). The Roche Nimblegen Human ChIP-chip 3x720K RefSeq ChIP-chip service and analysis were performed at MBL (Nagoya, Japan). The Roche Nimblegen Human ChIP-chip 3x720K RefSeq ChIP-chip service and analysis were performed at MBL (Nagoya, Japan). The Roche Nimblegen Human ChIP-chip 3x720K RefSeq ChIP-chip service and analysis were performed at MBL (Nagoya, Japan). The Roche Nimblegen Human ChIP-chip 3x720K RefSeq ChIP-chip service and analysis were performed at MBL (Nagoya, Japan). The Roche Nimblegen Human ChIP-chip 3x720K RefSeq ChIP-chip service and analysis were performed at MBL (Nagoya, Japan).

Results

Purification of a dDRG2-associated complex and identification of complex components

The DRG2 gene is highly conserved from Drosophila to humans and Drosophila DRG2 (dDRG2) protein is almost identical to human DRG2 protein [21].

To explore the novel factors interacting with dDRG2, which might shed light on its molecular functions in the nucleus, we endeavored to biochemically purify a dDRG2-associated complex. As the material for affinity purification, a Drosophila S2 cell line stably expressing the FLAG-His-tagged-dDRG2 protein was established. First, the nuclear extract, which had been extracted from the nucleus with 210 mM NaCl, was placed in contact with anti-FLAG M2 antibody agarose. After washing the agarose, purified factors were eluted with FLAG peptides. The derived eluent was subjected to further purification with nickel affinity resin for His-tag affinity purification (Figure 1(a)). The eluted sample was subjected to SDS-PAGE and silver staining (Figure 1(b)). Next, we applied more severe conditions to achieve nuclear extraction with 420 mM NaCl. The nuclear extract was placed in contact with anti-FLAG affinity agarose, and the eluted sample was subjected to SDS-PAGE and silver staining (Figure 2(a),(b)). Several specific bands were observed in the samples derived from dDRG2-expressing cells, but not in those from the mock-purified samples from wild type S2 cells (Figures 1(b) and 2(b)). The gel bands specific to the dDRG2 lane were excised and then subjected to identification by in-gel digestion followed by the peptide mass fingerprint method using MALDI-TOF/TOF mass spectrometry. This assay identified seven proteins, i.e. CG17514 / GCN1L1 (Figure 1(b)), heat shock protein cognate 4, CG9510 / ASL, isoforms B and E of eIF4B, RWDD1 (Drosophila RWDD1 (dRWDD1) | Drosophila RWDD1 (dRWDD1)), and CG31974 (Figure 2(b)). RWDD1 has already been reported as a binding partner of DRG2 [24], indicating our complex purification and protein identification experiments to have yielded reliable results. Furthermore, we attempted to isolate and identify the protein complex including dDRG2 protein. The extract purified with anti-FLAG antibody immunoprecipitation was fractionated by means of glycerol density gradient centrifugation (Figure 3(a)). The obtained samples were subjected to Western blotting with anti-DRG2 antibody and silver staining (Figure 3(b)). The dDRG2 protein was detected in fractions of 2-8 as well as 11-12, suggesting that dDRG2 forms multi-subunit complexes. Considering that the lowest fraction (11 and 12) represents products of protein aggregation, we focused on fraction 5 and endeavored to identify its components by applying mass spectrometry. This assay newly identified Nup107 (Drosophila Nup107 (dNup107)), in addition to dRWDD1, and the bait protein dDRG2 (Figure 3(c)). Nup107 is a component of the nuclear pore complex and is a member of the nucleoporin family [26]. dDRG2, dRWDD1, and dNup107 were fractionated into the same fraction on the glycerol density gradient, suggesting that these factors existed as one protein complex.

H2A.Z, DRG2, and Nup107 co-localized in the promoter region

To address whether these identified factors function together with H2A.Z in the same promoter regions of target genes, we performed ChIP analysis using the specific antibodies for H2A.Z, DRG2, and Nup107 in the human breast cancer cell line MCF7. The samples obtained by ChIP analysis were subjected to ChIP-chip analysis on the Roche Nimblegen Human ChIP-chip 3x720K ReSeq Promoter array. This assay revealed H2A.Z, DRG2, and Nup107 to be located on promoter regions of 8534, 9146 and 8551 genes,
identified genes are shown in ‘phosphoproteins’ defined as genes coding proteins that are largest category, which included 809 genes, was comprised of at least two isoforms due to pre-mRNA splicing. The second-of ‘alternative splicing variants’ defined as genes which have 1947 common genes by using DAVID bioinformatics resources. We next analyzed the functional characteristics of these 1947 common genes by using DAVID bioinformatics resources. The largest category, which included 871 genes, was comprised of ‘alternative splicing variants’ defined as genes which have at least two isoforms due to pre-mRNA splicing. The second-largest category, which included 809 genes, was comprised of ‘phosphoproteins’ defined as genes coding proteins that are post-translationally phosphorylated. Other characteristics of the identified genes are shown in Table 1(b).

Discussion

The possibility of direct interaction between H2A.Z and DRG2

In this study, we identified Nup107 as a factor physically interacting with DRG2, which interacted genetically with H2A.Z. In addition, we identified several factors supporting our speculations as to the functions of these three factors.

Although our results revealed genetic interactions between H2AvD and dDRG2 in Drosophila, we detected no physical interaction between H2A.Z and DRG2 in MCF7 cells by immunoprecipitation assay (data not shown). In fact, to our knowledge, there have been no reports focusing on direct interactions between H2A.Z and DRG2, though DRG1 protein reportedly interacts directly with the nucleosome including H2A.Z based on the results of nucleosome pull-down and proteomic analysis [27]. DRG1 protein is similar to DRG2 protein, and 58% of amino acid sequences in human DRG1 and DRG2 are reportedly identical [21]. Based on these observations, we can reasonably speculate that nucleosomes including H2A.Z have the potential to interact with DRG2.

Possible functions of DRG2 and RWDD1 in regulating epigenetics

DRG2 protein has a domain consisting of characteristic G-motifs that may serve as the core of GTPase activity, along with the C terminal TGS domain which is related to RNA binding [21]. Therefore, we speculate that DRG2 associates with mRNA and thereby plays roles in transcription, mRNA splicing, and translation. RWDD1, which is known to interact with DRG2, was reported to interact with androgen receptors and to act as a coactivator of androgen-dependent transcription [28-30]. If RWDD1 can function as a coactivator of other nuclear receptors including ERα/β, it would raise the possibility that DRG2 and RWDD1 function cooperatively in the transcription of ERα target genes.

Nup107 is a component of the nuclear pore complex (NPC). Nup107 has a leucine zipper, which may interact directly with DNA [26]. NPCs localize at the nuclear membrane and mainly function to regulate nuclear transport between the nucleoplasm and the cytoplasm. In addition, NPCs also function in gene activation and chromatin organization [31-33]. Therefore, there is a possibility that DRG2 and Nup107 are cooperatively associated with H2A.Z in nuclear export as well as transcription. As an example, it has been reported that, in yeast, associations between H2A.Z and NPCs regulate transcriptional memory, allowing early reactivation of transiently repressed genes anchored around the nuclear periphery [34].

The other proteins identified, GCN1L1 and eIF4B, also support our hypothesis that the complex functions as a mediator of transcription as well as facilitator of translation [35-38]. We recognize a very general consistency between the functions of the proteins identified and the characteristics of target genes regulated by H2A.Z, DRG2, and Nup107, as shown in Table 1(b).

The possible function of H2A.Z in cancer

Taking our results together with those of previous reports on H2A.Z, we speculate that the physiological function of H2A.Z in breast cancer might be associated with not only modulation of transcription but also mRNA splicing, nuclear export, and translation (Figure 4). Recently, epigenetic changes including H2A.Z have attracted attention as potential treatment targets [1,39-42]. Because altered expression patterns of H2A.Z as well as other H2A variants are associated with the development of several cancers, further analyses focusing, for example, on the implementation of high resolution mass spectrometry for each H2A variant [5], should be conducted in an effort to identify new therapeutic targets for breast cancer as well as other malignant tumors.

Conclusions

We revealed that DRG2 and Nup107 appear to be associated with epigenetic regulation via H2A.Z involving the promoter regions of specific genes in MCF7 breast cancer cells. DRG2 and Nup107 might be promising factors for elucidating the epigenetic impact of H2A.Z on breast cancer progression based on epigenetic alterations regulated by epidemiologic factors, such as lifetime exposure to E2 stimulation.
**Figure 4**

Theoretical model of the functions of H2A.Z with the DRG2-RWDD1-Nup107 complex in breast cancer.

**Table 1:** (a) Table and Venn diagram showing numbers of genes immunoprecipitated with antibodies against H2A.Z, DRG2, and Nup107 (b) Table showing the functional annotation chart for the 1947 genes common to the three factors, H2A.Z, DRG2, and Nup107.
Declarations
Ethics approval and consent to participate, Ethics approval and consent were unnecessary for the use of samples in this research.

Competing interests
The authors have no competing interests to declare.

Funding
This work was supported by JSPS KAKENHI (Grant-in-Aid for Young Scientists (B)); Grant Number JP 22770002. The authors declare that there was no other financial support for this research.

Authors’ contributions
MT wrote the manuscript. MT, SF, and YH edited the manuscript. MT and SF designed and/or performed the experiments.

Acknowledgements
We express our gratitude to Shun Sawatsubashi, Takuya Murata, Shuhei Kimura, and Saya Ito for their generous instructions and help with Drosophila genetics and protein purification. We also thank Yuki Imai, Kaoru Mogushi, Misa Imai, and Kousuke Ishikawa for helpful discussions pertaining to this research.
References

1. Rangasamy D (2010) Histone variant H2A.Z can serve as a new target for breast cancer therapy. Curr Med Chem 17: 3155-3161.

2. Colditz GA, K Bohike, Berkey CS (2014) Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat 145: 567-79.

3. Hervouet E, Carton PF, Jouvenot M, Delage-Mouroux R (2013) Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics 8: 237-245.

4. Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ, et al. (2013) Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 78: 161-170.

5. Monteiro FL, Baptista T, Amado F, Vitorino R, Jerónimo C, et al. (2014) Expression and functionality of histone H2A variants in cancer. Oncotarget 5: 3428-3443.

6. Venkatesh S, Workman JL (2015) Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol 16: 178-189.

7. Subramanian V, Fields PA, Boyer LA (2015) H2A.Z: a molecular rheostat for transcriptional control. F1000Prime Rep 7: 01.

8. Valdés-Mora F, Song JZ, Statham AL, Strbenac D, Robinson MD, et al. (2012) Acetylation of H2A.Z is a key epigenetic modification associated with gene derepression and epigenetic remodeling in cancer. Genome Res 22: 307-321.

9. Henikoff S, Smith MM (2015) Histone variants and epigenetics. Cold Spring Harb Perspect Biol 7: a019364.

10. Gévy N, Hardy S, Jacques PE, Lafllame L, Svetelis A, et al. (2009) Histone H2AZ is essential for estrogen receptor signaling. Genes Dev 23: 1522-1533.

11. Svetelis A, Geyv N, Grondin G, Gaudreau L (2010) H2A.Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle 9: 364-370.

12. Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, et al. (2008) Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 4: 188.

13. van Daal A, Elgin SC (1992) A histone variant, H2AvD, is essential in Drosophila melanogaster. Mol Biol Cell 3: 593-602.

14. Faast R, Thonglairoam V, Schulz TC, Beall J, Wells JR, et al. (2001) Histone variant H2A.Z is required for early mammalian development. Curr Biol 11: 1183-1177.

15. Fujiyama-Nakamura S, Ito S, Sawatsubashi S, Yamauchi Y, Suzuki E, et al. (2009) BTB protein, dKLHL18/CG3571, serves as an adaptor subunit for a dCul3 ubiquitin ligase complex. Genes Cells 14: 965-973.

16. Ito S, Fujiyama-Nakamura S, Kimura S, Lim J, Kamoshida Y, et al. (2012) Epigenetic silencing of core histone genes by HERS in Drosophila. Mol Biol Cell 45: 494-504.

17. Murata T, Suzuki E, Ito S, Sawatsubashi S, Zhao Y, et al. (2008) RNA-binding protein hoip accelerates polyQ-induced neurodegeneration in Drosophila. Biosci Biotechnol Biochem 72: 2255-2261.

18. Sawatsubashi S, et al. (2010) A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor. Genes Dev 24: 159-170.

19. Tanabe M, et al. (2008) Activation of facultatively silenced Drosophila loci associates with increased acetylation of histone H2AvD. Genes Cells 13: 1279-1288.

20. Kimura S, Loppin B (2015) Two bromodomain proteins functionally interact to recapitulate an essential BRDT-like function in Drosophila spermatocytes. Open Biol 5: 140-145.

21. Ishikawa K, Azuma S, Ikawa S, Morishita Y, Gohda J, et al. (2003) Cloning and characterization of Xenopus laevis dgr2, a member of the developmentally regulated GTP-binding protein subfamily. Gene 322: 105-112.

22. Ko MS, Lee UH, Kim SJ, Kim HJ, Park JJ, et al. (2004) Overexpression of DRG2 suppresses the growth of Jurkat T cells but does not induce apoptosis. Arch Biochem Biophys, 2004. 422(2): p. 137-44.

23. Song H, Kim SJ, Ko MS, Kim HJ, Heo JC, et al. (2004) Overexpression of DRG2 increases G2/M phase cells and decreases sensitivity to nocodazole-induced apoptosis. J Biochem 135: 331-335.

24. Ishikawa K, Azuma S, Ikawa S, Semba K, Inoue J (2005) Identification of DRG family regulatory proteins (DFRPs): specific regulation of DRG1 and DRG2. Genes Cells 10: 139-150.

25. Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N, Nozaki N (2008) The organization of histone H3 modifications as revealed by a panel of specific monoclonal antibodies. Cell Struct Funct 33: 61-73.

26. Radu A, Blobel G, Wozniak RW (1994) Nup107 is a novel nuclear pore complex protein that contains a leucine zipper. J Biol Chem 269: 17600-17605.

27. Fujimoto S, Seebart C, Guastafierro T, Prenni J, Caiafa P, et al. (2012) Proteome analysis of protein partners to nucleosomes containing canonical H2A or the variant histones H2A.Z or H2A.X. Biol Chem 393: 47-61.

28. Kang N, Duan L, Tang L, Liu S, Li C, et al. (2008) Identification and characterization of a novel thymus aging related protein Rwdd1. Cell Mol Immunol 5: 279-285.

29. Kang N, Chen D, Wang L, Duan L, Liu S, et al. (2008) Rwdd1, a thymus aging related molecule, is a new member of the intrinsically unstructured protein family. Cell Mol Immunol 5: 333-339.

30. Grotsch H, Kunert M, Mooslehner KA, Gao Z, Struve D, et al. (2012) RWDD1 interacts with the ligand binding domain of the androgen receptor and acts as a coactivator of androgen-dependent transactivation. Mol Cell Endocrinol 358: 53-62.

31. Hsu C, Corces VK (2010) Nups take leave of the nuclear envelope to regulate transcription. Cell 140: 306-308.

32. Capelson M, Liang Y, Schulte R, Mair W, Wagner U, et al. (2010) Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 140: 372-383.

33. Kalverda B, Pickersgill H, Shloma VV, Fornerod M (2010) Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 140: 360-371.

34. Light WH, Brickner DG, Brand VR, Brickner JH (2010) Interaction of a DNA zip code with the nuclear pore complex promotes H2A.Z incorporation and INO1 transcriptional memory. Mol Cell 40: 112-125.

35. Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N (2010) elf4F4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle 9: 4106-4109.

36. Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, et al. (2014) Abrogating phosphorylation of elf4F4 is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. Breast Cancer Res Treat 147: 283-293.
37 Knuesel MT, Meyer KD, Bernecky C, Taatjes DJ, et al. (2009) The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. Genes Dev 23: 439-451.

38 Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ (2009) The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol 29: 650-661.

39 Kutanzi KR, Koturbash I, Kovalchuk O (2010) Reversibility of premalignant estrogen-induced epigenetic changes. Cell Cycle 9: 3078-3084.

40 Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, et al. (2009) Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69: 3802-3809.

41 Connolly R, Stearns V (2012) Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 17: 191-204.

42 Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, et al. (2015) Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. Mol Cell 59: 75-88.